Freshly baked: Pretzel Therapeutics takes out the oven mitts to drug diseases in the powerhouse of the cell
After helping co-found Vir Biotechnology and lead the biotech’s business development through the first few years, including a rare emergency use authorization for a Covid-19 treatment, Jay Parrish has found a new home at the pretzel powerhouse.
Focused on the so-called powerhouse of the cell, the mitochondria, Pretzel Therapeutics emerged Monday with $72.5 million in Series A backing from ARCH Venture Partners and Mubadala Capital, along with a syndicate of other investors.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,400+ biopharma pros reading Endpoints daily — and it's free.